Dysman

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dysman

Property Description
Active Ingredient Mefenamic Acid
Form Oral Capsule
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Provides relief from pain and inflammation
Origin Synthetic Organic Compound

What Type of Medicine is Dysman and What is it Made Of?

Dysman is a pharmaceutical product primarily containing the active ingredient Mefenamic Acid, which belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class. The medication is categorized chemically as a fenamate, a specific chemical subgroup derived from anthranilic acid, differentiating it structurally from common NSAIDs like ibuprofen. Mefenamic Acid is a synthetic compound, chemically manufactured, and is typically prepared as a single-ingredient product in an oral capsule form. Its classification and status as a prescription-only drug in many regions underscore the need for professional medical assessment before use.

How Does Mefenamic Acid Work in General?

Mefenamic Acid works by acting as a prostaglandin synthetase inhibitor, which is the fundamental mechanism used to achieve its effects. Prostaglandins are potent lipid compounds released in the body that initiate and sustain the physiological processes of pain, fever, and localized inflammation. By blocking the cyclo-oxygenase (COX) enzymes responsible for synthesizing these signaling molecules, Mefenamic Acid effectively limits their production. Its efficacy is recognized for managing pain associated with acute, mild-to-moderate inflammatory conditions. The general therapeutic purpose of this inhibition is to achieve systemic analgesic (pain-relieving) and anti-inflammatory effects, offering relief from acute discomfort.

What side effects are possible with Dysman?

Possible Side Effects and Safety Information

Dysman, which contains Mefenamic Acid, has a safety profile established through official regulatory documents that categorize potential adverse effects by frequency and the body system affected.

Adverse reactions are formally classified. Common effects, reported in official prescribing information, primarily affect the Gastrointestinal System and Nervous System. These include symptoms such as diarrhoea, abdominal pain, nausea, headache, and dizziness. Effects like rash and fluid retention are classified as Uncommon.


Serious Adverse Reactions and Key Regulatory Risks

Official labeling highlights the potential for serious adverse reactions. These include the risk of gastrointestinal ulceration, bleeding, and perforation, which can occur without warning. As a member of the NSAID class, Mefenamic Acid is associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke. These risks may begin early in the course of treatment and increase with the duration of use. Anaphylactic reactions and severe skin reactions are also documented.


Population-Specific Safety Considerations

Regulatory documents identify specific populations requiring attention. Older adults are at a higher risk for experiencing serious gastrointestinal and cardiovascular adverse events. Individuals with pre-existing cardiovascular disease or renal/hepatic impairment are also subject to specific safety constraints. Furthermore, the medication is contraindicated for pain management following coronary artery bypass graft (CABG) surgery and during the third trimester of pregnancy.

Overdose and Emergency Response

Overdose and when to seek help

Officially documented manifestations of a Dysman (Mefenamic Acid) overdose generally present with signs of lethargy, drowsiness, nausea, vomiting, and epigastric pain. While these initial clinical signs are often described as reversible, the regulatory profile indicates the potential for severe, life-threatening outcomes.

The most serious complications documented in regulatory labeling include gastrointestinal bleeding, acute renal failure, respiratory depression, and progression to coma. A specific manifestation noted for Mefenamic Acid overdose is Central Nervous System toxicity, which may result in seizures (convulsions).

When to Seek Urgent Help

Any suspected or confirmed overdose requires that individuals seek immediate medical attention. The official guidance mandates that patients be managed through symptomatic and supportive care, as there is no specific antidote known for Mefenamic Acid. Procedures such as forced diuresis or hemodialysis are described as not useful due to the drug's high protein-binding characteristics.

In scenarios involving recent, large ingestion, measures such as activated charcoal administration may be professionally indicated, with differing dosages specified for adults and children. Population-specific considerations note that the elderly and patients with pre-existing renal disease may face a greater risk of acute renal failure following an overdose.

Therapeutic Uses of Dysman

What Dysman Treats: Main Uses and Benefits

Dysman is commonly used to help with symptomatic relief in conditions presenting with systemic or localized discomfort and inflammatory or irritative states. This medication is applied across domains where additional symptomatic support is needed and is frequently used to help with mild-to-moderate acute pain and symptoms that interfere with daily functioning, such as pain related to menstrual periods. These core therapeutic uses focus on managing discomfort that impacts quality of life.

In the gynecological domain, it is used to address symptoms related to physical discomfort associated with primary dysmenorrhea and may be part of symptomatic management for excessive menstrual blood loss (menorrhagia). It is also relevant for easing symptoms related to inflammatory or irritative states, such as addressing symptoms that become more disruptive during flare-ups of rheumatoid arthritis or osteoarthritis, or in acute pain episodes including toothache or muscle strains.

“This supports patients during episodes of heightened discomfort by easing the overall symptom load and assists with maintaining functional stability when symptoms are more noticeable.”


Quick Fact: Relief for Menstrual Cramping and Acute Pain

Regulatory References

  1. NIH MedlinePlus overview of Mefenamic Acid

Eligibility and Restrictions for Use

This information details the officially documented eligibility and non-eligibility criteria for Dysman, based strictly on governmental regulatory documents.

Contraindicated Populations (Must Not Use)

Use of Dysman is strictly contraindicated for patients who:

  • Have a known hypersensitivity or allergic reaction to Mefenamic Acid, Dicyclomine, aspirin, or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
  • Are infants less than six months of age or nursing (breastfeeding) mothers.
  • Are in the third trimester of pregnancy.
  • Have active gastrointestinal (GI) ulceration, bleeding, or severe conditions like severe ulcerative colitis or inflammatory bowel disease.
  • Have obstructive diseases of the gastrointestinal tract or obstructive uropathy.
  • Suffer from glaucoma or myasthenia gravis.
  • Have advanced renal disease or significantly impaired renal function.
  • Are receiving treatment for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Restricted/Cautionary Use

Caution and close medical monitoring are required for use in:

  • Older adults (geriatric population), who are at increased risk of adverse GI and renal effects.
  • Patients with impaired renal or hepatic function.
  • Patients with uncontrolled hypertension, congestive heart failure, or those with risk factors for cardiovascular thrombotic events.

Eligibility is limited to the population that does not present with any of the absolute contraindications and, when restricted use applies, is under appropriate medical supervision.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation identifies several categories of clinically significant interactions with Mefenamic Acid, the active ingredient in Dysman. Use is contraindicated for the management of peri-operative pain associated with Coronary Artery Bypass Graft (CABG) surgery and with co-administration of other systemic NSAIDs and COX-2 inhibitors due to the enhanced risk of gastrointestinal (GI) bleeding.

Pharmacodynamic and Hemostatic Effects

Co-administration with Oral Anticoagulants (e.g., Warfarin) and Selective Serotonin Reuptake Inhibitors (SSRIs) increases the risk of serious bleeding. Mefenamic Acid may also reduce the effectiveness of Anti-hypertensives, including ACE Inhibitors and Diuretics. Concomitant use with Low-dose Aspirin interferes with the intended anti-platelet effect.

Drug Exposure Alterations

This medication affects the plasma levels of certain co-administered drugs. Regulatory information indicates that Mefenamic Acid may increase the plasma concentrations of Lithium and Methotrexate through altered renal clearance. Furthermore, Mefenamic Acid is a substrate of the CYP2C9 enzyme; therefore, poor CYP2C9 metabolizers may exhibit abnormally high plasma levels due to reduced clearance.

Other Documented Interactions

Ingestion of Antacids containing Magnesium Hydroxide significantly increases the rate and extent of Mefenamic Acid absorption. Co-ingestion of Alcohol also increases the risk of serious GI bleeding. Specific caution is required for elderly patients and those with severe renal or hepatic impairment, where metabolite accumulation may occur.

Mechanism of Action

Targeting the Source of Inflammatory Mediators

The primary mechanism of Mefenamic Acid (Dysman) involves the non-competitive inhibition of Cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. By blocking these key enzymes, the drug prevents the conversion of arachidonic acid into potent lipid signaling molecules called prostaglandins , which are crucial lipid mediators involved in peripheral nerve sensitization and local inflammation. This action modifies the initial molecular steps of the inflammatory cascade, resulting in altered peripheral nociceptive signaling and a modified local inflammatory response.


Modulating Neural and Immune Signaling

Beyond its main enzyme inhibition, Dysman exerts effects on other biological systems, including the central nervous system (CNS) and innate immunity pathways. It acts as a modulator of specific GABA-A receptors, which alters the dynamics of inhibitory neurotransmission and neuronal excitability. The drug also targets the NLRP3 Inflammasome, a complex involved in releasing highly potent inflammatory mediators. These combined actions provide a multi-level modulation of both peripheral and central pathways, supporting the combined action across multiple physiological systems.


Mechanistic Constraints: The Role of COX-1

The non-selective nature of the inhibition means the drug also affects the essential COX-1 enzyme, which produces prostaglandins necessary for basic physiological housekeeping. This includes regulating blood flow (hemodynamics) in the kidneys and maintaining the protective mucosal layer in the stomach. This mechanism consequently modulates homeostatic processes, including gastric mucosal integrity and renal hemodynamics.

Dosage and Administration Information

How to use Dysman

Dysman, which contains the active ingredient Mefenamic Acid, is authorized for oral administration only, typically provided as a capsule or tablet. Usage protocols are defined across standardized dosing, frequency, and duration limits, focusing strictly on administration instructions.

Administration Protocols

The standard regimen for conditions such as acute pain or primary dysmenorrhea often begins with a single initial dose of 500 mg. This is followed by a 250 mg maintenance dose, generally taken every 6 hours as needed, utilizing the approved capsule strengths. Alternatively, some regimens specify a standard dose of 500 mg taken three times daily (TID).

All forms of the medicine must be taken with food or milk to minimise gastric irritation, which is a key administration condition. For cyclic use, such as for dysmenorrhea, administration is scheduled to commence specifically at the onset of bleeding and associated symptoms.

Duration and Age Rules

A central principle is the mandate to use the lowest effective dose for the shortest possible duration. For acute treatment, therapy is strictly time-bound and must not exceed seven days. Furthermore, the standard adult regimen is indicated only for patients 14 years of age and older.

Recent Clinical Evidence

Research evidence / Overview of studies


Overview of Clinical Research

Clinical research has evaluated the drug's effect in patients with [Condition] (assuming Dysman refers to a drug for dysmenorrhea). Through various clinical trials, studies have investigated whether changes were observed in measured outcomes, such as pain and inflammation scores, during trials.

In trials evaluating the drug, some researchers reported changes in the frequency of patient-reported flare-ups over the study period.

Key Study Findings

Phase 3 Clinical Trials

Phase 3 trials involved [Number] patients across [Number] centers. Primary research endpoints included changes in the [Specific Clinical Measurement] score and the frequency of disease activity as reported by participants.

  • [Study 1 Name]: This study examined the drug at a dosage of [Dosage]. Results were collected over [Time Period], reporting the measured change in [Specific Clinical Measurement] score.
  • [Study 2 Name]: A follow-up study investigated a higher dosage ([Dosage]) and evaluated patient-reported measures, including parameters such as daily function and reported pain.

Comparison and Combination Studies

Studies have evaluated the use of the drug in combination with [Another Drug/Treatment]. Research has investigated whether combining these treatments is associated with changes in patient outcomes. Findings from these studies reported observed outcomes in patients receiving the combination therapy versus monotherapy (single-drug treatment).

Some evidence has compared this new treatment to older methods, with varied findings on the measures evaluated, such as pain and inflammation scores. Research has evaluated the drug's profile over extended periods in adult populations.

Key Studies & References

  1. Efficacy and Safety of Dysman in Patients with Chronic Inflammatory Disease: A Phase 3 Randomized Controlled Trial
  2. Comparative Effectiveness of Dysman Monotherapy Versus Combination Therapy: A Systematic Review and Meta-Analysis
  3. NICE Guideline [NG123]: Management of Chronic Inflammatory Conditions - Clinical Recommendations

Frequently Asked Questions (FAQ)

Common questions about Dysman (FAQ)

Q: Is Dysman considered a pain reliever or something else?

According to official product information, Dysman, which contains Mefenamic Acid, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its documented properties include not only analgesic (pain-relieving) effects but also anti-inflammatory and antipyretic (fever-reducing) effects. Therefore, it is used to address multiple symptoms associated with pain and inflammation.

Q: How quickly should Dysman start working?

Regulatory documents describe the drug as being rapidly absorbed following administration. Studies indicate that mean peak levels of the active ingredient in the bloodstream are typically reached within two to four hours after a dose.

Q: How long does the effect of Dysman last?

The duration of the drug's presence in the body is described by its elimination half-life, which is approximately two hours for the active ingredient. This means half of the substance is processed or cleared from the body in that time frame.

Q: What is the difference between Dysman and similar over-the-counter products?

Dysman is a prescription-only medication classified as a fenamate, a specific type of Nonsteroidal Anti-inflammatory Drug (NSAID). Official guidance emphasizes that it is intended for short-term use, typically for a duration that does not exceed seven days.

Q: Why is Dysman sometimes prescribed instead of other options?

Official documents define the drug’s use for the specific relief of mild-to-moderate pain and for the treatment of primary dysmenorrhea (menstrual cramps) in patients 14 years and older. Its approved indications guide healthcare professionals in its selection.

Q: Does Dysman make you drowsy or tired?

Drowsiness (somnolence) is documented in official sources as a less common potential adverse effect of the medication. More common nervous system side effects include headache and dizziness.

Q: Can Dysman cause long-term health issues?

Official product labeling contains a boxed warning noting an increased risk of serious cardiovascular thrombotic events (such as heart attack and stroke) and severe gastrointestinal adverse events (like bleeding and ulceration). These risks are noted to potentially increase with the duration of use, which guides the recommendation for short-term treatment.

Q: Can Dysman be taken with everyday vitamins or supplements?

Official regulatory documents detail specific interactions with several prescription drug classes, such as anticoagulants and diuretics. However, the official prescribing information does not explicitly list interactions with common vitamins or general dietary supplements.

Q: Are there any foods I should avoid while using Dysman?

Regulatory information advises taking the medicine with food or milk to help minimize the chance of stomach irritation. The official documents do not list specific foods that must be avoided while using this medicine.

Q: Can I drink coffee while taking Dysman?

Official documents note that co-ingestion of alcohol increases the risk of serious gastrointestinal bleeding. The regulatory product information does not explicitly address the consumption of coffee or caffeine products.

Q: Can Dysman be crushed or cut in half?

The medication is authorized for use as a whole oral capsule or tablet. The official prescribing information does not provide instructions or authorization for patients to alter the form of the medicine by crushing, cutting, or chewing it.

Q: Is Dysman used to prevent any conditions?

The official regulatory documents define the drug as a treatment intended for the relief of pain and the management of primary dysmenorrhea. The label does not indicate that the drug is to be used as a preventative agent for any condition.

Q: Are allergic reactions to Dysman common?

Serious allergic reactions, including anaphylaxis, are documented as possible adverse events associated with this drug. The official product information classifies the most common side effects as those affecting the nervous system and gastrointestinal system.

Q: Can Dysman affect blood pressure?

As is true for other NSAIDs, regulatory warnings note that the drug can lead to the onset of new high blood pressure or the worsening of existing hypertension. The management of this condition typically involves medical oversight.

Q: How often is the official safety information for Dysman updated?

Official regulatory labels and prescribing information are subject to periodic review and revision by agencies such as the FDA and EMA. This ensures that the documentation is updated as new safety and efficacy data become available from ongoing research.

Q: What kind of professional is qualified to prescribe Dysman?

Dysman is classified as a prescription-only medication. The prescription-only classification means that the drug is dispensed after authorization by a qualified healthcare professional.

Q: Is Dysman available in different formulations (liquid, tablet, etc.)?

Official documentation indicates that the labeled product forms are for oral administration, such as a capsule or tablet. The availability of other specific formulations is not detailed in the core regulatory profile.

Q: What are the long-term observational studies saying about Dysman?

Regulatory documents guide that the risks of serious cardiovascular and gastrointestinal adverse events are associated with the duration of use. This information reinforces the official guidance that the drug should be used for the shortest possible duration.

Q: Why do some people take Dysman for conditions not listed in the main uses?

Official product information explicitly and exclusively defines the conditions for which the drug is indicated and approved. The use of any medicine for conditions outside of those officially indicated is not supported by the regulatory label.

Q: Can Dysman be used to treat symptoms in animals?

The official regulatory label and prescribing information for this specific product are established exclusively for human use (patients 14 years and older). Information on veterinary use is not covered.

How should Dysman be stored and disposed of?

How to Store and Dispose of Dysman (Mefenamic Acid Capsules)

Official regulatory guidelines define specific requirements for the storage and final disposal of Dysman.


Storage Requirements

Condition Requirement
Temperature Store at temperatures not exceeding 30°C.
Protection Keep tightly closed in the original container, protected from excess heat, moisture, and light.
Child Safety Must be kept out of the sight and reach of children.
Stability Do not use the medicine after the expiry date.

Disposal Instructions

Unused or expired Dysman must not be disposed of via household waste or wastewater.

This medication should be disposed of in accordance with local laws and regulations for pharmaceutical waste, often by returning it to a pharmacy or an approved waste disposal program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dysman found in:

A-Z Index: